An important reason to pursue PSMA-targeted imaging of ICC is the prospect of PSMA-targeted peptide radioligand therapy (e.g., 177Lu-PSMA-617) for patients with ICC with high PSMA expression. The gene discussed is FOLH1; the disease is intrahepatic cholangiocarcinoma.